Development of a radioligand receptor assay for measuring follitropin in serum

Application to premature ovarian failure

Alan L. Schneyer, Patrick M. Sluss, Randall W. Whitcomb, Janet E. Hall, William F. Crowley, Ruth G. Freeman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We have developed a radioligand receptor assay (RRA) with sufficient sensitivity and specificity for quantifying follitropin (FSH) in unextracted serum samples. Standard curves prepared by adding pituitary FSH to either buffer or gonadotropin-free serum were parallel and statistically indistinguishable in this assay, whereas gonadotropin-free serum alone had no activity. Cross-reactivity with related pituitary hormones was negligible. Pituitary FSH was calibrated with commonly used reference preparations so that RRA results could be compared with RIA results for identical standards. The patterns in daily blood samples in six normal menstrual cycles were similar by both methods. The mean RIA:RIA ratio in both the follicular and luteal phases was between 0.6 and 0.7, and at mid-cycle decreased to 0.48, suggesting an alteration of isohormone composition at mid-cycle. In 27 women with premature ovarian failure, RRA:RIA ratios ranged from below the RRA minimum detectable dose to 4.6, suggesting that immunoreactive FSH might not be capable of binding to the FSH receptor in some patients, whereas in patients with high RRA:RIA ratios, circulating inhibitors of FSH receptor binding might be present and perhaps contributing to the observed ovarian failure. Use of this RRA in conjunction with RIA and in vitro bioassays may better define the relative contribution of FSH isohormones, autocrine or paracrine modulators of FSH bioactivity, and FSH-receptor binding competitors to the "total FSH biological signal" as detected by the gonadal FSH receptor.

Original languageEnglish (US)
Pages (from-to)506-514
Number of pages9
JournalClinical Chemistry
Volume37
Issue number4
StatePublished - 1991

Fingerprint

Primary Ovarian Insufficiency
Radioligand Assay
Follicle Stimulating Hormone
FSH Receptors
Assays
Serum
Gonadotropins
Follicular Phase
Pituitary Hormones
Luteal Phase
Menstrual Cycle
Bioassay
Biological Assay
Bioactivity
Buffers
Modulators
Blood
Sensitivity and Specificity
Chemical analysis

Keywords

  • Competitors for receptor binding
  • Menstrual cycle
  • Pituitary hormones
  • Radioimmunoassay compared

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Schneyer, A. L., Sluss, P. M., Whitcomb, R. W., Hall, J. E., Crowley, W. F., & Freeman, R. G. (1991). Development of a radioligand receptor assay for measuring follitropin in serum: Application to premature ovarian failure. Clinical Chemistry, 37(4), 506-514.

Development of a radioligand receptor assay for measuring follitropin in serum : Application to premature ovarian failure. / Schneyer, Alan L.; Sluss, Patrick M.; Whitcomb, Randall W.; Hall, Janet E.; Crowley, William F.; Freeman, Ruth G.

In: Clinical Chemistry, Vol. 37, No. 4, 1991, p. 506-514.

Research output: Contribution to journalArticle

Schneyer, AL, Sluss, PM, Whitcomb, RW, Hall, JE, Crowley, WF & Freeman, RG 1991, 'Development of a radioligand receptor assay for measuring follitropin in serum: Application to premature ovarian failure', Clinical Chemistry, vol. 37, no. 4, pp. 506-514.
Schneyer AL, Sluss PM, Whitcomb RW, Hall JE, Crowley WF, Freeman RG. Development of a radioligand receptor assay for measuring follitropin in serum: Application to premature ovarian failure. Clinical Chemistry. 1991;37(4):506-514.
Schneyer, Alan L. ; Sluss, Patrick M. ; Whitcomb, Randall W. ; Hall, Janet E. ; Crowley, William F. ; Freeman, Ruth G. / Development of a radioligand receptor assay for measuring follitropin in serum : Application to premature ovarian failure. In: Clinical Chemistry. 1991 ; Vol. 37, No. 4. pp. 506-514.
@article{ab2334cc2c6048caa04ead1ac27c9ea5,
title = "Development of a radioligand receptor assay for measuring follitropin in serum: Application to premature ovarian failure",
abstract = "We have developed a radioligand receptor assay (RRA) with sufficient sensitivity and specificity for quantifying follitropin (FSH) in unextracted serum samples. Standard curves prepared by adding pituitary FSH to either buffer or gonadotropin-free serum were parallel and statistically indistinguishable in this assay, whereas gonadotropin-free serum alone had no activity. Cross-reactivity with related pituitary hormones was negligible. Pituitary FSH was calibrated with commonly used reference preparations so that RRA results could be compared with RIA results for identical standards. The patterns in daily blood samples in six normal menstrual cycles were similar by both methods. The mean RIA:RIA ratio in both the follicular and luteal phases was between 0.6 and 0.7, and at mid-cycle decreased to 0.48, suggesting an alteration of isohormone composition at mid-cycle. In 27 women with premature ovarian failure, RRA:RIA ratios ranged from below the RRA minimum detectable dose to 4.6, suggesting that immunoreactive FSH might not be capable of binding to the FSH receptor in some patients, whereas in patients with high RRA:RIA ratios, circulating inhibitors of FSH receptor binding might be present and perhaps contributing to the observed ovarian failure. Use of this RRA in conjunction with RIA and in vitro bioassays may better define the relative contribution of FSH isohormones, autocrine or paracrine modulators of FSH bioactivity, and FSH-receptor binding competitors to the {"}total FSH biological signal{"} as detected by the gonadal FSH receptor.",
keywords = "Competitors for receptor binding, Menstrual cycle, Pituitary hormones, Radioimmunoassay compared",
author = "Schneyer, {Alan L.} and Sluss, {Patrick M.} and Whitcomb, {Randall W.} and Hall, {Janet E.} and Crowley, {William F.} and Freeman, {Ruth G.}",
year = "1991",
language = "English (US)",
volume = "37",
pages = "506--514",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "4",

}

TY - JOUR

T1 - Development of a radioligand receptor assay for measuring follitropin in serum

T2 - Application to premature ovarian failure

AU - Schneyer, Alan L.

AU - Sluss, Patrick M.

AU - Whitcomb, Randall W.

AU - Hall, Janet E.

AU - Crowley, William F.

AU - Freeman, Ruth G.

PY - 1991

Y1 - 1991

N2 - We have developed a radioligand receptor assay (RRA) with sufficient sensitivity and specificity for quantifying follitropin (FSH) in unextracted serum samples. Standard curves prepared by adding pituitary FSH to either buffer or gonadotropin-free serum were parallel and statistically indistinguishable in this assay, whereas gonadotropin-free serum alone had no activity. Cross-reactivity with related pituitary hormones was negligible. Pituitary FSH was calibrated with commonly used reference preparations so that RRA results could be compared with RIA results for identical standards. The patterns in daily blood samples in six normal menstrual cycles were similar by both methods. The mean RIA:RIA ratio in both the follicular and luteal phases was between 0.6 and 0.7, and at mid-cycle decreased to 0.48, suggesting an alteration of isohormone composition at mid-cycle. In 27 women with premature ovarian failure, RRA:RIA ratios ranged from below the RRA minimum detectable dose to 4.6, suggesting that immunoreactive FSH might not be capable of binding to the FSH receptor in some patients, whereas in patients with high RRA:RIA ratios, circulating inhibitors of FSH receptor binding might be present and perhaps contributing to the observed ovarian failure. Use of this RRA in conjunction with RIA and in vitro bioassays may better define the relative contribution of FSH isohormones, autocrine or paracrine modulators of FSH bioactivity, and FSH-receptor binding competitors to the "total FSH biological signal" as detected by the gonadal FSH receptor.

AB - We have developed a radioligand receptor assay (RRA) with sufficient sensitivity and specificity for quantifying follitropin (FSH) in unextracted serum samples. Standard curves prepared by adding pituitary FSH to either buffer or gonadotropin-free serum were parallel and statistically indistinguishable in this assay, whereas gonadotropin-free serum alone had no activity. Cross-reactivity with related pituitary hormones was negligible. Pituitary FSH was calibrated with commonly used reference preparations so that RRA results could be compared with RIA results for identical standards. The patterns in daily blood samples in six normal menstrual cycles were similar by both methods. The mean RIA:RIA ratio in both the follicular and luteal phases was between 0.6 and 0.7, and at mid-cycle decreased to 0.48, suggesting an alteration of isohormone composition at mid-cycle. In 27 women with premature ovarian failure, RRA:RIA ratios ranged from below the RRA minimum detectable dose to 4.6, suggesting that immunoreactive FSH might not be capable of binding to the FSH receptor in some patients, whereas in patients with high RRA:RIA ratios, circulating inhibitors of FSH receptor binding might be present and perhaps contributing to the observed ovarian failure. Use of this RRA in conjunction with RIA and in vitro bioassays may better define the relative contribution of FSH isohormones, autocrine or paracrine modulators of FSH bioactivity, and FSH-receptor binding competitors to the "total FSH biological signal" as detected by the gonadal FSH receptor.

KW - Competitors for receptor binding

KW - Menstrual cycle

KW - Pituitary hormones

KW - Radioimmunoassay compared

UR - http://www.scopus.com/inward/record.url?scp=0026396052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026396052&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 506

EP - 514

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 4

ER -